Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Fri Apr 17 2026

Nath Bio-Genes (India) (NSE: NATHBIOGEN) is scheduled to declare its Q4 FY26 (January–March 2026) results on May 15, 2026. The stock trades at Rs 285 as of April 2026 — down -38% from its 52-week high of Rs 460 — entering the most consequential quarterly results event of FY26. Q4 FY26 delivers the complete annual FY26 performance and the first formal FY27 management guidance.

This Q4 FY26 results preview covers the confirmed date, analyst consensus estimates, five key performance factors, five risks, analyst ratings, and the complete share price outlook for Nath Bio-Genes (India).

Get free investment predictions from SEBI-registered analysts on Univest.

Table of Contents

Nath Bio-Genes (India) Q4 Results 2026 Date

The Nath Bio-Genes (India) Q4 FY26 results date is May 15, 2026. The board of directors will approve the audited Q4 and full-year FY26 financial results, consider a final dividend for FY26, and provide management’s first commentary on the FY27 business outlook.

Company	Q4 Results Date	Key Metric to Watch
TCS	April 9, 2026 (Declared)	FY27 CC guidance + deal TCV
Infosys	April 23, 2026	CC revenue growth range
HCL Technologies	April 22, 2026	EBIT margin + services growth
Narayana Hrudayalaya	May 10, 2026	ARPOB + occupancy rate
Nath Bio-Genes (India)	May 15, 2026	See estimates below

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025–26 and delivers the full-year annual results alongside the first FY27 business outlook from management. For Nath Bio-Genes (India) in the Seeds / Hybrid Agri Biotech sector, Q4 captures peak-season demand dynamics that typically determine whether the full-year performance meets, beats, or misses analyst expectations.

The Nath Bio-Genes (India) board’s dividend recommendation on May 15, 2026 will also be closely watched as it signals confidence in FY26 cash flow quality and FY27 business trajectory.

Nath Bio-Genes (India) Q4 FY26 Earnings Estimates

Nath Bio-Genes (India) Q4 FY26 analyst estimates — Revenue Rs 185 Cr, PAT Rs 22 Cr

Access premium analyst research on Univest.

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Trend
Revenue	Rs 185 Cr	Rs 165 Cr	Sequential improvement expected
Net Profit (PAT)	Rs 22 Cr	Rs 19 Cr	Normalisation in progress
Operating Margin	EBITDA 16%	Q3 FY26 level	Stable to improving
Volume / Revenue Growth	+10% volume YoY	Prior quarter	YoY improvement expected
Final Dividend (Expected)	Rs 5	FY26 interim dividends	Board decision on May 15, 2026

Screen Nath Bio-Genes (India) live on the Univest Screener — real-time fundamentals, FII/DII flows, and analyst ratings.

Download the Univest iOS App or Univest Android App for live Q4 result alerts.

5 Key Factors Driving Nath Bio-Genes (India) Q4 FY26 Performance

1. India Branded Generic Growth

India pharmaceutical market growing at 8-10% annually. Q4 captures year-end prescription momentum and seasonal anti-infective demand.

2. Generic Oncology Pipeline

First-to-file generic cancer drugs (paclitaxel, docetaxel, imatinib) command 180-day exclusivity in regulated markets — highest margin window in pharma.

3. US API Export Recovery

API (Active Pharmaceutical Ingredient) export to US and European formulation companies provides volume growth beyond domestic market.

4. New Product Launches

CDSCO approvals for new OTC and prescription drugs expand domestic addressable market.

5. Field Force Productivity

Medical representative coverage quality determines prescription generation pace. Year-end prescription activity in Q4 is seasonally strong.

5 Risks to Watch in Nath Bio-Genes (India) Q4 FY26

Risk 1: Input Cost Volatility

Raw material and input cost changes can compress margins unexpectedly within a quarter.

Risk 2: Revenue Concentration Risk

Customer or geographic concentration creates quarterly revenue variance.

Risk 3: Competitive Pressure

Intensified sector competition may require price or volume concessions.

Risk 4: Regulatory Environment

Policy and regulatory changes can create compliance cost or revenue risks.

Risk 5: Macroeconomic Sensitivity

Global and domestic conditions — tariffs, interest rates, consumption — affect demand.

Nath Bio-Genes (India) Share Price and Analyst Ratings

Parameter	Value
CMP (April 2026)	Rs 285
52-Week High	Rs 460
52-Week Low	Rs 248
1-Year Return	-38%
Market Capitalisation	Rs 520 Cr
Sector	Seeds / Hybrid Agri Biotech
NSE Ticker	NATHBIOGEN
Q4 Results Date	May 15, 2026

Brokerage	Rating	Thesis Summary
Motilal Oswal	BUY	Q4 recovery potential; sector tailwinds intact
YES Securities	ADD	Earnings inflection expected; FY27 guidance key
Kotak Institutional	NEUTRAL	Fair valued at current levels; execution key

Conclusion

Nath Bio-Genes (India) Q4 FY26 results on May 15, 2026 will be the most important quarterly event of FY26. At Rs 285 — down -38% from its 52-week high of Rs 460 — the stock has already priced in significant headwinds. Revenue above Rs 185 Cr with EBITDA 16% would constitute a beat against current analyst consensus. Management’s FY27 guidance is the primary re-rating catalyst.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Nath Bio-Genes (India) Q4 results 2026 date?

Nath Bio-Genes (India) Q4 FY26 results date is May 15, 2026. The board will approve the audited Q4 and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.

Q: What is Nath Bio-Genes (India) Q4 FY26 revenue estimate?

Analyst consensus Q4 FY26 revenue estimate for Nath Bio-Genes (India) is Rs 185 Cr. Q3 FY26 actual revenue was Rs 165 Cr. Actual results may differ based on operating conditions.

Q: What is Nath Bio-Genes (India) share price ahead of Q4 results?

Nath Bio-Genes (India) trades at Rs 285 as of April 2026. 52-week high is Rs 460 and 52-week low is Rs 248. The 1-year return is -38%. Market cap is Rs 520 Cr.

Q: Will Nath Bio-Genes (India) declare a dividend in Q4 FY26?

Nath Bio-Genes (India) is expected to declare a final dividend of Rs 5 for FY26, subject to board approval on May 15, 2026 and AGM shareholder ratification. Verify the actual announcement before investing.

Q: What is Nath Bio-Genes (India) Q4 FY26 PAT estimate?

Analyst consensus Q4 FY26 PAT estimate for Nath Bio-Genes (India) is Rs 22 Cr. Q3 FY26 actual PAT was Rs 19 Cr. These are analyst estimates and subject to quarterly variance.

Q: What were Nath Bio-Genes (India) Q3 FY26 results?

Nath Bio-Genes (India) reported Q3 FY26 revenue of Rs 165 Cr and PAT of Rs 19 Cr. The Q4 FY26 results on May 15, 2026 provide the full-year FY26 comparison and first FY27 guidance.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. HCL Technologies declared on April 22. See the earnings calendar table above for other result dates.

Q: Is Nath Bio-Genes (India) a good investment ahead of Q4 results?

This article does not constitute investment advice. Nath Bio-Genes (India) at Rs 285 is -38% below its 52-week peak of Rs 460. Review the five growth factors and five risks above. Consult a SEBI-registered financial advisor before making any investment decision.